Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00462579 · ClinicalTrials.gov registry record
Risk Factors for Carbapenem-resistant Acinetobacter Baumannii
A clinical trial, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 100
- Enrollment target
NCT00462579 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 100 participants.
The verdict
NCT00462579 has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
It has been demonstrated that panresistant strains of Acinetobacter species may be selected by antibiotic use \[4\], may be transmitted from person to person \[5\], and may be passed via environmental contamination \[6\]. Surveillance for panresistant Acinetobacter species should be a priority, given the lack of antibiotic options for the treatment of these infections. There are currently no data on the antibiotic susceptibility of Acinetobacter species or on the rates of panresistant organisms. The elucidation of potential risk factors for resistant strains of Acinetobacter is therefore an important task, and the use of alternative antibiotics should be considered in ICUs where these strains are endemic.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2007-04 |
| Est. Completion | 2017-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00462579
The ClinicalTrials.gov registry entry for NCT00462579 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00462579 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00462579 about?
NCT00462579 is a clinical study titled "Risk Factors for Carbapenem-resistant Acinetobacter Baumannii". It has been demonstrated that panresistant strains of Acinetobacter species may be selected by antibiotic use \[4\], may be transmitted from person to person \[5\], and may be passed via environmental contamination \[6\]. Surveillance for panresistant Acinetobacter species should be a priority, give...
What is the current status of trial NCT00462579?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2007-04. Estimated completion is 2017-06.
Who is sponsoring clinical trial NCT00462579?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.